What is pathophysiology of Alzheimer?

['ⵙⵎⴷ ⵜⴰⴱⵔⴰⵜ ⴰⴷ']

ⵎⴰⵜⵜⴰ ⵜⴰⴷⵍⴰ ⵏ ⵜⵎⴰⴹⵓⵏⵉⵏ ⵏ ⴰⵍⵣⵀⴰⵢⵎⵔ?

ⵜⴰⴱⴰⵜⵓⴼⵉⵣⵉⵓⵍⵓⵊⵉⵜ ⵏ ⵜⵎⴰⴹⵓⵏⵜ ⵏ ⴰⵍⵣⵀⴰⵢⵎⵉⵔ (AD) ⵜⴳⴰ ⵢⴰⵜ ⵜⵎⴳⴳⵉⵜ ⵉⵔⵡⵉⵏ ⵏⵏⴰ ⵢⵓⵎⵥⵏ ⴰⵙⵎⵓⵏ ⵏ ⵉⴱⵔⵓⵜⵉⵏⵏ ⵓⵔ ⵉⵍⴳⵉⵏⵏ, ⴷ ⵓⵙⵙⵓⴹⵏ, ⴷ ⵜⴰⵡⵓⵔⵉ ⵓⵔ ⵉⵖⵓⴷⴰⵏ ⵏ ⵉⵏⵢⵓⵔⵓⵏⵏ.

ⵙⵉⵏ ⵉⵙⴽⴽⵉⵍⵏ ⵉⴷⵙⵍⴰⵏⵏ ⵏ ⵡⴰⵟⵟⴰⵏ ⵏ ⴰⵍⴷⵓⵏⵉⵙⵢⴰ ⴳⴰⵏ ⵉⵍⵍⴰ ⴱⵍⴰⴽ ⴰⵎⵉⵍⵓⵉⴷ-ⴱⵉⵜⴰ (Aβ) ⴷ ⵜⴱⵍⴽⵉⵎⵉⵏ ⵏ ⵉⵏⵢⵔⵓⴼⵉⴱⵔⵉⵍⵍⴰⵔⵉ (NFTs) ⴳ ⵓⵏⵍⵍⵉ.

ⴷⴰ ⵜⵜⵓⵙⴽⴰⵔⵏⵜ ⵜⵇⴰⵕⵉⴹⵉⵏ ⵏ ⴰⵎⵉⵍⵓⵉⴷ-ⴱⵉⵜⴰ ⵍⵍⵉⵖ ⴷⴰ ⵜⵜⵓⵙⵏⴼⵍⵏ ⵉⴼⵔⴷⵉⵙⵏ ⵏ ⵓⴱⵕⵓⵜⵉⵏ ⴰⵎⵣⵡⴰⵔⵓ ⵏ ⴰⵎⵉⵍⵓⵉⴷ (APP) ⵙ ⵜⵏⴰⴼⵓⵜⵉⵏ ⵏ ⵉⵏⵣⵉⵎⵏ ⴰⴼⴰⴷ ⴰⴷ ⵜⵜⵓⵙⴽⴰⵔⵏⵜ ⵜⴱⵢⴱⵜⵉⴷⵉⵏ ⵏ Aβ.

ⴷⴰ ⵜⵜⵎⵓⵏⵏⵜ ⵜⴱⵢⴱⵜⵉⴷⵉⵏ ⴰⴷ ⴰⵔ ⵜⵜⵓⵙⴽⴰⵔⵏⵜ ⵉⴼⵉⵍⴰⵏ ⵓⵔ ⵉⵜⵜⵎⵔⵖⴰⵏ ⵏⵏⴰ ⵉⵜⵜⵎⵓⵏⵏ ⴳ ⴱⵕⵕⴰ ⵏ ⵉⵏⵢⵓⵔⵓⵏⵏ, ⴰⵔ ⵜⵜⵔⵥⵥⵓⵏ ⴰⵎⵢⴰⵡⴰⴹ ⵏ ⵜⵖⵔⴰⵙⵜ ⵙ ⵜⵖⵔⴰⵙⵜ ⴰⵔ ⵜⵜⴰⵡⵉⵏ ⵙ ⵜⵎⵜⵜⴰⵏⵜ ⵏ ⵉⵏⵢⵓⵔⵓⵏⵏ.

ⴷⴰ ⵜⵜⵡⴰⵍⴰ ⵎⴰⵙⴷ ⴰⵙⵎⵓⵏ ⵏ ⵜⴱⵍⴽⵉⵎⵉⵏ ⵏ ⴰⴱⵉⵜⴰ ⵉⴳⴰ ⵢⴰⵏ ⵙⴳ ⵉⵎⵣⵣⵓⵜⵏ ⵉⵎⵣⵡⵓⵔⴰ ⴳ ⵓⴱⵓⵖⵍⵓ ⵏ ⵡⴰⵟⵟⴰⵏ ⵏ ⴰⵍⴷⵣⴰⵢⵔ, ⴰⵔ ⵜⵜⵡⴰⵍⴰ ⵎⴰⵙⴷ ⴰⵔ ⵉⵜⵜⴰⵡⵙ ⴳ ⵜⵎⴳⴳⵉⵜ ⵏ ⵓⵙⵙⵏⴼⵍ ⵏ ⵜⴰⴳⴳⴰⵢⵜ ⵏ ⵓⵏⵍⵍⵉ.

ⴷⴰ ⵜⵜⵓⵙⴽⴰⵔⵏⵜ ⵜⵇⵛⵛⵓⴹⵉⵏ ⵏ ⵉⵏⵢⵓⵔⵓⴼⵉⴱⵔⵉⵍⴰⵔⵉⵢⵏ ⵍⵍⵉⵖ ⴷⴰ ⵉⵜⵜⵓⵙⴽⴰⵔ ⵓⴱⵕⵓⵜⵉⵏ ⵟⴰⵡ ⵙ ⵓⴽⵙⴰⵢ ⵉⴳⴳⵓⵜⵏ ⴰⵔ ⵉⵜⵜⵓⵙⴽⴰⵔ ⵉⴼⵉⵍⴰⵏ ⵓⵔ ⵉⴳⵉⵏ ⵉⵎⴰⴷⴷⴰⵔⵏ ⴳ ⵓⴳⵏⵙⵓ ⵏ ⵉⵏⵢⵓⵔⵓⵏⵏ.

ⴷⴰ ⵜⵜⴱⴷⴷⴰⴷⵏ ⵜⵇⵕⵕⴰⴹⵉⵏ ⴰⴷ ⵜⵉⵡⵓⵔⵉ ⵜⴰⵣⴷⴷⴰⴳⵜ ⵏ ⵜⵢⵓⵡⵏⵉⵏ ⵜⵉⵥⵥⵉⴹⵕⴰⵏⵉⵏ, ⵏⵏⴰ ⵉⴳⴰⵏ ⵜⵉⵔⵙⴰⵍⵜ ⵉ ⵓⵙⵎⵓⵜⵜⴳ ⵏ ⵉⵎⵙⵎⴰⵜⵜⴰⵢⵏ ⴷ ⵜⵎⵜⵜⴰ ⵢⴰⴹⵏⵉⵏ ⴳ ⵡⴰⵏⵙⴰ ⵏ ⵉⵏⵢⵓⵔⵓⵏ.

ⴷⴰ ⵜⵜⴰⵡⵉⵏⵜ ⵜⵉⴼⵍⵓⵜⵉⵏ ⵙ ⵜⵉⴳⵉⵔⴰ ⵖⵔ ⵜⵎⵜⵜⴰⵏⵜ ⵏ ⵉⵏⵢⵓⵔⵓⵏⵏ ⵉⵜⵜⵓⵙⵏⴼⴰⵍⵏ.

ⴷⴰ ⵉⵜⵜⵓⵔⴰⵔ ⵓⴽⵙⵉⵊⵉⵏ ⴰⵡⴷ ⵢⴰⵜ ⵜⵉⵍⴰⵍⵜ ⴳ ⵜⴱⴰⵜⵓⴼⵉⵣⵉⵓⵍⵓⵊⵉⵜ ⵏ ⵡⴰⵟⵟⴰⵏ ⵏ ⴰⵍⴷⵣⴰⵢⵔ.

ⴷⴰ ⵉⵜⵜⵔⴰⵔ ⵓⵏⴳⵔⴰⵡ ⵏ ⵜⵎⵔⴰⵔⵓⵜ ⵏ ⵜⴰⴷⵓⵙⵉ ⵅⴼ ⵓⵙⵎⵓⵏ ⵏ ⵜⴱⵍⴽⵉⵎⵉⵏ ⵏ Aβ ⴷ NFT ⵙ ⵓⵙⵙⵓⴼⵖ ⵏ ⵜⵛⵉⵜⵓⴽⵉⵏⵉⵏ ⵜⵉⵙⵓⵊⵊⵉⵢⵏ, ⵏⵏⴰ ⵉⵖⵉⵏ ⴰⴷ ⵙⵙⵖⵓⴷⵓⵏ ⴰⵙⵏⴳⵓ ⵏ ⵉⵏⵢⵓⵔⵓⵏⵏ.

ⵙ ⵓⵙⵎⵓⵏ, ⵉⵍⵍⴰ ⵉⵏⵥⴰⵜⵏ ⵏⵏⴰ ⵉⵎⵎⴰⵍⵏ ⵎⴰⵙⴷ ⴰⵙⵎⵎⴰⵎⴷ ⵏ ⵓⴽⵙⵉⴷ, ⴷ ⵜⵣⴳⴰⵍⵜ ⵏ ⵜⵡⵓⵔⵉ ⵏ ⵎⵉⵜⵓⴽⵓⵏⴷⵔⵉⵢ, ⴷ ⵓⵙⵏⴼⵍ ⵏ ⵓⵙⵎⵎⴰⵎ ⵏ ⵍⴳⵍⵓⴽⵓⵙ ⴷⴰ ⵉⵜⵜⴰⵡⵙⵏ ⴳ ⵜⴱⴰⵜⵓⴼⵉⵣⵉⵢⵓⵍⵓⵊⵉⵜ ⵏ ⵡⴰⵟⵟⴰⵏ ⵏ ⴰⵍⴷⵣⴰⵢⵔ.

ⵣⵎⵔⵏ ⵉⵎⴳⴳⵉⵜⵏ ⴰⴷ ⵙⵙⵉⴳⴳⵣⵏ ⵜⴰⵡⵓⵔⵉ ⵏ ⵉⵏⵢⵓⵔⵓⵏⵏ ⴷ ⵜⵎⵜⵜⴰⵏⵜ, ⵙ ⵓⵙⵔⵇⴱ ⵏ ⵜⵎⵔⵏⵉⵡⵜ ⵏ ⵜⵎⵙⴽⵔⵜ ⵏ ⵜⵎⴰⴹⵓⵏⵜ.

ⵙ ⵓⵎⴰⵜⴰ, ⵜⴳⴰ ⵜⴱⴰⵜⵓⴼⵉⵣⵉⵓⵍⵓⵊⵉⵜ ⵏ ⵡⴰⵟⵟⴰⵏ ⵏ ⴰⵍⴷⵣⴰⵢⵔ ⵢⴰⵜ ⵜⵎⵢⴰⵖⵜ ⵜⴰⵎⵔⵡⴰⵏⵜ ⵏ ⴽⵉⴳⴰⵏ ⵏ ⵉⵎⵙⴽⴰⵔⵏ ⵏⵏⴰ ⴷ ⵢⵓⵡⵉⵏ ⴳ ⵜⴳⵉⵔⴰ ⵖⵔ ⵜⵣⵔⵉⴳⵣⵜ ⵜⴰⵎⵖⵓⵔⴰⵏⵜ ⴳ ⵜⵡⵓⵔⵉ ⵏ ⵓⵙⵡⵉⵏⴳⵎ ⴷ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ ⵏ ⵜⵍⴽⴰⵎⵉⵏ.

['ⵉⵙⵓⵎⴰⵔ']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nemeroff CB: The preeminent role of neuropeptide systems in the early pathophysiology of Alzheimer disease: up with corticotropin-releasing factor, down with acetylcholine. Arch Gen Psychiatry. 1999, 56 (11): 991-2.

Skoog I, Kalaria RN, Breteler MM: Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord. , 13 Suppl 3 (): S106-14.

Proft J, Weiss N: Jekyll and Hide: The two faces of amyloid β. Commun Integr Biol. 2012, 5 (5): 405-7.

Whitehouse PJ, Hedreen JC, White CL, Price DL: Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol. 1983, 13 (3): 243-8.

Casadesus G, Moreira PI, Nunomura A, Siedlak SL, Bligh-Glover W, Balraj E, Petot G, Smith MA, Perry G: Indices of metabolic dysfunction and oxidative stress. Neurochem Res. , 32 (4-5): 717-22.

Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, Duro G, Lio D, Matranga D, Pellicanò M, Rizzo C, Scapagnini G, Vasto S: Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res. , 13 (2-3): 301-13.

Raskind MA, Peskind ER: Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer Dis Assoc Disord. 1994, 8 Suppl 3 (): 54-60.

Schindler SE, McConathy J, Ances BM, Diamond MI: Advances in diagnostic testing for Alzheimer disease. Mo Med. , 110 (5): 401-5.

Singh VK: Immune-activation model in Alzheimer disease. Mol Chem Neuropathol. , 28 (1-3): 105-11.

['ⴰⵙⴱⴷⵉⴷ: ⴰⵎⵙⵏⵉⵊⵊⵉ']

['ⴰⵙⵉⵜ ⴰⴷ ⵉⵜⵜⵓⴼⴽⴰ ⵖⴰⵙ ⵉ ⵓⵡⵜⵜⴰⵙ ⵏ ⵓⵙⵙⵍⵎⴷ ⴷ ⵓⵙⵏⵖⵎⵙ, ⵓⵔ ⵉⴳⵉ ⴰⵙⴼⴽ ⵏ ⵓⵎⵛⴰⵡⴰⵕ ⵏ ⵓⴷⵓⵙⵜⵓⵔ ⵏⵖⴷ ⵜⵡⵓⵔⵉⵡⵉⵏ ⵜⵉⵣⵣⵓⵍⴰⵏⵉⵏ.']

['ⵓⵔ ⵉⵇⵇⵉⵏ ⴰⴷ ⵉⵜⵜⵓⵙⵎⵔⵙ ⵓⵎⵍⴰⵏ ⵉⵜⵜⵓⴼⴽⴰⵏ ⴳ ⵓⵙⵎⵔⵙ ⵏ ⵓⵙⵎⵉⴳⵍ ⵏⵖⴷ ⵓⵙⵓⵊⵊⵉ ⵏ ⵜⵎⵓⴽⵔⵉⵙⵜ ⵏ ⵜⴷⵓⵙⵉ ⵏⵖⴷ ⵜⵎⴰⴹⵓⵏⵜ, ⴷ ⵡⵉⵏⵏⴰ ⵉⵔⴰⵏ ⴰⵙⵇⵇⵙⵉ ⴰⵎⵙⵏⵉⵊⵊⵉ ⴰⵡⵏ ⵉⵜⵜⵓⴼⴽⴰⵏ ⵉⵇⵇⴰⵏ ⴰⴷ ⵙⴰⵡⵍⵏ ⴷ ⵓⵎⵙⵏⵉⵊⵊⵉ ⵉⵜⵜⵓⵥⵍⴰⵢⵏ.']

['ⵙ ⵡⴰⵍⵍⵍⵉ ⵉⵜⵜⵓⵢⴰⵏⵏⴰ, ⵜⴰⵔⴰⵜⵙⴰ ⵏ ⵓⵏⵢⵓⵔⴰⵍ ⵏⵏⴰ ⵉⵜⵜⴰⴽⴽⴰⵏ ⵜⵉⵎⵔⴰⵔⵓⵜⵉⵏ ⵉ ⵉⵙⵇⵙⵉⵜⵏ, ⵓⵔ ⴷⴰ ⵜⵜⵉⵍⵉ ⴰⴽⴽⵡ ⵜⵓⵙⴷⵉⴷⵜ ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵓⵡⵏⵖ ⵏ ⵓⵟⵟⵓⵏ. ⵙ ⵓⵎⴷⵢⴰ, ⵓⵟⵟⵓⵏ ⵏ ⵎⴷⴷⵏ ⵉⵜⵜⵓⵙⵏⴼⴰⵍⵏ ⵖⴼ ⵜⵎⴰⴹⵓⵏⵜ ⵉⵥⵍⵉⵏ.']

['ⵚⵓⴰⵍ ⵙⵓⵍ ⴰⵙⵏⴰⵍ ⵏ ⵓⵊⵉⵊⵊⵉ ⵏⵏⴽ ⵏⵖⴷ ⴽⵔⴰ ⵏ ⵓⵎⵙⵙⵉⵡⵍ ⵏ ⵜⴷⵓⵙⵉ ⵢⴰⴹⵏ ⵉⵇⴱⵍⵏ ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵡⴰⴷⴷⴰⴷ ⵏ ⵜⴷⵓⵙⵉ. ⵓⵔ ⴰⴽⴽⵡ ⴰⴷ ⵜⵙⵙⴼⵍⴷ ⴰⵙⵏⴰⵍ ⵏ ⵓⵊⵉⵊⵊⵉ ⴰⵣⵣⵓⵍⴰⵏ ⵏⵖⴷ ⴰⴷ ⵜⵣⴰⵢⴷ ⴳ ⵓⵙⵓⵜⴳ ⵏⵏⵙ ⴰⵛⴽⵓ ⵏⵜⵜⴰⵜ ⴰⵢⴷ ⵜⵙⵙⵖⵔⴷ ⴳ ⵓⵙⵉⵜ ⴰⴷ. ⵎⴽ ⵜⵓⵔⴷⴰ ⴰⴷ ⵖⵓⵔⴽ ⵉⵍⵍⴰ ⵡⴰⴷⴷⴰⴷ ⵏ ⵜⴷⵓⵙⵉ ⵉⵣⵣⴳⵔⵏ, ⵙⵎⴷ 911 ⵏⵖⴷ ⴰⴷ ⴷⵉⴷⵜ ⵜⴰⵍⵙ ⴷⴰⵔ ⵜⴰⴷⴰⵍⴰ ⵏ ⵓⵣⵣⵔⴰⵢ ⵏ ⵣⵉⴽⴽ. ⵓⵔ ⵜⵍⵍⴰ ⵜⵓⵇⵇⵏⴰ ⵏ ⵓⵊⵉⵊⵊⵉ ⴷ ⵓⵎⵏⵉⴳ ⵙ ⵓⵙⵉⵜ ⴰⴷ ⵏⵖⴷ ⵓⵙⵎⵔⵙ ⵏⵏⵙ. ⵓⵔ ⴷⴰ ⵜⵙⴽⴰⵔ ⴱⵢⵓⵎⵉⴷⵍⵉⴱ ⵏⵖⴷ ⵉⵎⵙⵡⵓⵔⵉⵏ ⵏⵏⵙ ⵏⵖⴷ ⴽⵔⴰ ⵏ ⵓⵎⴷⵔⴰⵡ ⴳ ⵓⵙⵉⵜ ⴰⴷ ⴽⵔⴰ ⵏ ⵓⵙⵎⴷⵢⴰ, ⵙ ⵡⴰⵡⴰⵍ ⵏⵖⴷ ⵙ ⵓⵙⵏⵓⵎⵍ, ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵉⵏⵖⵎⵉⵙⵏ ⵉⵍⵍⴰⵏ ⴳ ⵓⴷⵖⴰⵔ ⴰⴷ ⵏⵖⴷ ⵓⵙⵎⵔⵙ ⵏⵏⵙ.']

['ⴰⵙⴱⴰⴷⵓ: ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⴼⵓⵙ']

['ⴰⵛⵔⵓⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ']

['ⵎⴽ ⵜⵛⵛⵉⵖⴰⵍⴷ ⵙ ⵜⵛⵛⵉⵢⵜ ⵎⴰⵙⴷ ⴽⵔⴰ ⵏ ⵜⵓⵎⴰⵢⵜ ⵏⵖⴷ ⵉⵙⵏⴼⴰⵔⵏ ⵏⵏⴰ ⵉⵜⵜⵓⴼⴽⴰⵏ ⴳ ⵡⴰⵙⵉⵜ ⵏⵏⵓⵏ ⵏⵖⴷ ⵜⵉⵙⵏⵙⵉ ⵏⵏⵓⵏ ⴷⴰ ⵉⴽⵛⵎⵏ ⴳ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵣⵔⴼ ⵏⵏⵓⵏ, ⵜⵣⵎⵔⴷ ⴰⴷ ⵜⴰⵍⵙⴷ (ⵏⵖ ⴰⵎⴷⵢⴰⵣ ⵏⵏⴽ) ⴰⴷ ⵜⵙⵏⵎⵍⴷ ⵉ ⵡⴰⵙⵉⵜ ⵏⵏⵓⵏ ⵙ ⵓⵙⵓⵜⵔ ⵏ ⵓⵙⵙⵉⴷⴼ ⵏ ⵜⵓⵎⴰⵢⵜ ⵏⵖⴷ ⵉⵙⵏⴼⴰⵔⵏ, ⵏⵖⴷ ⴰⴷ ⵜⴱⴷⴷⴷ ⵜⵉⵍⵉⵜ ⵏⵏⵙⵏ.']

['ⵉⵏⴰⵓⴰⵏ ⴰⵂⴰⵏ ⴰⴾⵜⴰⴱ ⵙ ⴰⵍⴾⵉⵜⵜⴰⴱ ⵙ ⵎⵢⵍ (ⵉⴾⵉⴰⴷ ⵙ ⴰⴾⵜⴰⴱ "ⵎⵢⵍ" ⵉ ⵎⵢⵍ)']

['DMCA ⵜⵙⵙⵓⵜⵔ ⴰⵙⵎⵉⵙⵉ ⵏⵏⴽ ⵏ ⵓⵎⴳⴰⵍ ⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ ⵉⴽⵛⵎ ⴳ ⵓⵙⵎⵎⴰⵍ ⴰⴷ: (1) ⴰⵙⵏⵓⵎⵍ ⵏ ⵜⵡⵓⵔⵉ ⵉⵃⴱⴰⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ ⵏⵏⴰ ⵉⴳⴰⵏ ⴰⵙⵏⵜⵍ ⵏ ⵓⵎⴳⴰⵍ; (2) ⴰⵙⵏⵓⵎⵍ ⵏ ⵜⵓⵎⴰⵢⵜ ⵉⵃⴱⴰⵏ ⵉⵣⵔⴼⴰⵏ ⴷ ⵉⵏⵖⵎⵉⵙⵏ ⵉⵅⵚⵚⴰⵏ ⴰⴼⴰⴷ ⴰⴷ ⵏⴰⴼ ⵜⵓⵎⴰⵢⵜ; (3) ⵉⵏⵖⵎⵉⵙⵏ ⵏ ⵓⵎⵢⴰⵡⴰⴹ ⴰⴽⴷⴽ, ⴳ ⵉⵍⵍⴰ ⵡⴰⵏⵙⴰ ⵏⵏⴽ, ⵓⵟⵟⵓⵏ ⵏ ⵜⵉⵍⵉⴼⵓⵏ ⴷ ⵡⴰⵏⵙⴰ ⵏ ⵓⵍⵉⴽⵜⵕⵓⵏ; (4) ⴰⵙⵉⵡⴹ ⵏⵏⴽ ⵎⴰⵙ ⴷⴰⵔⴽ ⵜⴰⵍⵍⵉⵍⵜ ⵉⵖⵓⴷⴰⵏ ⵏ ⵓⵙⵏⴽⴷ ⵎⴰⵙ ⵜⵓⵎⴰⵢⵜ ⵙ ⵜⵖⴰⵔⴰⵙⵜ ⵏⵏⴰ ⵜⵙⵙⵔⴳⴰⵍ ⵓⵔ ⵜⴽⴽⵉ ⵜⵓⵔⴰⴳⵜ ⵙⴳ ⵖⵓⵔ ⵡⴰⵏⵏⴰ ⵉⵟⵟⴰⴼⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ, ⵏⵖⴷ ⴰⵎⴷⵢⴰⵣ ⵏⵏⵙ, ⵏⵖⴷ ⵙ ⵓⵙⵡⵓⵔⵉ ⵏ ⴽⵔⴰ ⵏ ⵓⵙⵍⴳⵏ; ']

['(5) ⴰⵙⵉⵙⵙⵉⴾⵉ ⵏⵢⵜ, ⵉⴾⴼⴰⵏ ⵙ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⵜⵉⴷⵉⵜ, ⴰⵙ ⵉⵙⴰⵍⴰⵏ ⵓⵉⵏ ⵢⵎⵢⵍ ⵏⴰⵙⴰⵏ ⵓⵉⵏ ⵢⵎⵢⵍ ⵓⵉⵏ ⴰⴾⴰⵉⴰⴷ ⴷ ⴰⵙ ⵉⵍⴰ ⴰⴾⴰⵉⴰⴷ ⵉ ⴰⵙⵓⵋ ⵏ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵜⵉⵏ ⴰⴾⴰⵉⴰⴷ ⵓⵉⵏ ⴰⴾⴰⵉⴰⴷ ⵓⵉ ⴰⵋⵋⴰⵏⵢⵏ']

['ⴷ (6) ⴰⴾⴰⵔⵓⵙ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⵎⵓⵙⵏⴰⵜ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵎⵢⵗ ⵓⴰ ⵉⵋⵋⴰⵏ ⵙ ⵢⵎⵢⵍ ⵏ ⵎⵓⵙⵏⴰⵜ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ']

['ⴰⴾⴰⵉⴰⴷ ⵏ ⴰⵙⴰⴾⵏⵢ ⵏ ⵉⵙⴰⵍⴰⵏ ⵓⵉⵏ ⴰⵋⵋⵓⵜⵏⵢⵏ ⴰⴷⴷⵓⴱⴰⵜ ⴰⴷ ⵢⵈⵈⵉⵍ ⴰⵙⵉⵓⴰⴷ ⵏ ⴰⴾⴰⵉⴰⴷ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏⵢⵜ']

['ⴰⵎⵢⴰⵡⴰⴹ']

['ⵙⵓⴾⵢⵍ ⵉⵢⵎⴰⵍ ⵉⵢⵎⴰ ⵙ ⴽⴰⴾⴰⵎⴰⵍ ⴰⵙⵉⵙⵜⴰⵏ/ⴰⵙⵓⵋ']

What is pathophysiology of alzheimer?

The pathophysiology of Alzheimer's disease (AD) is a complex process that involves the accumulation of abnormal proteins, inflammation, and neuronal dysfunction.

The two main hallmarks of AD are the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain.

Amyloid-beta plaques are formed when fragments of the amyloid precursor protein (APP) are cleaved by enzymes to form Aβ peptides.

These peptides aggregate and form insoluble fibrils that accumulate outside neurons, disrupting cell-to-cell communication and leading to neuronal death.

The accumulation of Aβ plaques is thought to be one of the earliest events in the development of AD, and it is believed to contribute to the neurodegenerative process.

Neurofibrillary tangles are formed when the protein tau becomes hyperphosphorylated and forms abnormal filaments inside neurons.

These tangles disrupt the normal functioning of the microtubules, which are essential for the transport of nutrients and other materials within the neuron.

The tangles eventually lead to the death of the affected neurons.

Inflammation also plays a role in the pathophysiology of AD.

The immune system responds to the accumulation of Aβ plaques and NFTs by releasing pro-inflammatory cytokines, which can exacerbate the damage to neurons.

Additionally, there is evidence that oxidative stress, mitochondrial dysfunction, and impaired glucose metabolism contribute to the pathophysiology of AD.

These factors can lead to neuronal dysfunction and death, further exacerbating the disease process.

Overall, the pathophysiology of AD is a complex interplay of multiple factors that ultimately lead to the progressive decline in cognitive function and memory loss that characterizes the disease.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.

['ⴰⵜⵜⴰⵢⵏ']

['ⴷⴰ ⵉⵙⵙⵎⵔⴰⵙ ⴱⵢⵓ ⵎⵉⴷⵍⵍⵉⴱ ⵉⵎⴰⵙⵙⵏ ⵏ ⵓⵙⵉⴳⴳⵍ ⵉⵎⵉⴽⵙⵉⵍⵏ (ⴰⵍⴳⵓⵔⵉⵜⵎ ⵏ ⵓⵍⵎⵎⵓⴷ ⵏ ⵉⵎⵉⵙ) ⵉ ⵓⵙⵓⴼⵖ ⵏ ⵉⵎⵣⵉⵏⵏ ⵏ ⵉⵙⵇⵙⵉⵜⵏ ⴷ ⵜⵎⵔⴰⵔⵓⵜⵉⵏ.']

['ⴷⴰ ⵏⵙⵙⵏⵜⵉ ⵙ 35 ⵎⵍⵢⵓⵏ ⵏ ⵜⵥⵕⵉⴳⵉⵏ ⵏ ⵜⵙⵏⵉⵊⵊⵉⵜ ⵜⴰⴱⵢⵓⵎⵉⴷⵉⴽⵜ ⵏ ⴱⴰⴱⵎⵉⴷ/ⵎⵉⴷⵍⵉⵏ. ⵓⵍⴰ ⴰⵡⴷ ⵜⵉⴼⵔⴽⵉⵏ ⵏ ⵡⵉⴱ ⵏ ⵔⴰⴼⵉⵏⴷⵡⵉⴱ.']

['ⴰⵜ-ⵓ-ⴰⵗ "ⴰⵍⵓⴰⵈⴰⵏ" ⴰⴷ "ⴰⴾⴼⴰⵣ"']